The Effects of 3-Month Rosuvastatin Adjuvant Therapy on Post Thrombotic Syndrome following Deep Vein Thrombosis; a Randomized Clinical Trial
Archives of Academic Emergency Medicine,
Vol. 11 No. 1 (2023),
15 Aban 2022
,
Page e43
https://doi.org/10.22037/aaem.v11i1.1872
Abstract
Introduction: Statins are known to have anticoagulation and anti-inflammatory effects. This study aimed to investigate the effect of Rosuvastatin in reduction of post thrombotic syndrome (PTS) following deep vein thrombosis (DVT).
Methods: In this randomized clinical trial, patients who were diagnosed with DVT of lower extremity were randomly assigned to 4 treatment groups: group 1: Warfarin, group 2: Warfarin + Rosuvastatin, group 3: Rivaroxaban, and group 4: Rivaroxaban + Rosuvastatin. The treatments were followed for 3 months and prevalence of PTS (as primary outcome), as well as the changes in serum levels of D-dimer and C reactive protein (CRP), and the extent of thrombosis before and after the intervention (as secondary outcomes) were compared between groups.
Results: 182 patients with the mean age of 55.22 ± 4.1 years finished the trial period (51.64% male). There was no significant difference between the groups regarding the baseline characteristics. Based on the Brandjes score, 31 (17.03%) patients had PTS at the end of the study. The occurrence of PTS was significantly lower in the groups taking statins (p<0.0001). Although the change in the mean difference of legs circumference before and after intervention, were significant in all groups (p < 0.05), the differences was more prominent in groups 2 and 4 (p < 0.0001). After 3 months of taking medication, decrease of CRP was more prominent in the statin groups (p = 0.001), and most cases with normal CRP were in statin groups. Among the patients with the serum D-dimer level above 10000 ng/mL, patients in the statin groups experienced significantly more reduction in D-dimer levels than the other groups (p<0.001).
Conclusion: Rosuvastatin administration in combination with rivaroxaban or warfarin significantly reduces the level of inflammatory factors including CRP and D-dimer, compared to patients receiving anticoagulants alone. Rosuvastatin administration can significantly reduce the incidence of PTS and cause a difference in the size of the lower limbs within 3 months.
- Venous thrombosis
- Postthrombotic syndrome
- Rosuvastatin calcium
- Rivaroxaban
- Warfarin
- Anticoagulants
How to Cite
References
Hull RD, Lip GY, Leung L. Venous thromboembolism: anticoagulation after initial management. U: UpToDate, Leung LLK, Mandel J ur UpToDate available from https://www.uptodate.com/contents/venous-thromboembolism-anticoagulation-after-initial-management/print. 2017.
Bozorgmehr R, Toudeshki KK, Saadati N, Ehsanfar N, Pishgahi M. Association between Anatomic Configuration of Thrombosis with Clinical Symptoms and Risk factors in Admitted Patients with Deep Vein Thrombosis. MHJ. 2021; 5(1), e27-e27.
Pishgahi M, Bozorgmehr R, Toudeshki KK, Forouzannia A. Evaluation of Association between duration of Hospitalization in-Patient with Deep Venous Thrombosis and the type of Treatment Considering the Effect of Comorbid Diseases. MHJ. 2021;5(1):e14-e.
Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130(18):1636-61.
Kahn SR, Mathes BM. Post-thrombotic (postphlebitic) syndrome. UpToDate Waltham, MA: UpToDate Inc Available from https://www.uptodate.com/contents/post-thrombotic-postphlebitic-syndrome/contributors. 2019.
Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron M-J, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008;149(10):698-707.
Meissner MH, Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J. Vasc. Surg. 2012;55(5):1449-62.
Enden T, Haig Y, Kløw N-E, Slagsvold C-E, Sandvik L, Ghanima W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. The Lancet. 2012;379(9810):31-8.
Du G-C, Zhang M-C, Zhao J-C. Catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of proximal deep vein thrombosis-a meta-analysis. Vasa. 2015;44(3):195-202.
Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs. Circulation. 2013;127(2):251-7.
San Norberto EM, Gastambide MV, Taylor JH, García-Saiz I, Vaquero C. Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis. Vasa. 2016;45(2):133-40.
Albert MA, Danielson E, Rifai N, Ridker PM, Investigators P, Investigators P. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64-70.
Adams NB, Lutsey PL, Folsom AR, Herrington DH, Sibley CT, Zakai NA, et al. Statin therapy and levels of hemostatic factors in a healthy population: the Multi‐Ethnic Study of Atherosclerosis. J. Thromb. Haemost. 2013;11(6):1078-84.
Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler. Thromb. Vasc. Biol. 2005;25(2):287-94.
Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear factor-κB in endothelial cells. J. Cardiovasc. Pharmacol. 2007;49(6):376-83.
Gertz K, Laufs U, Lindauer U, Nickenig G, Böhm M, Dirnagl U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34(2):551-7.
Baldwin M, Moore H, Rudarakanchana N, Gohel M, Davies A. Post‐thrombotic syndrome: a clinical review. J. Thromb. Haemost. 2013;11(5):795-805.
DeRoo S, Deatrick KB, Henke PK. The vessel wall: A forgotten player in post thrombotic syndrome. J. Thromb. Haemost. 2010;104(10):681-92.
Delluc A, Ghanima W, Kovacs MJ, Shivakumar S, Kahn SR, Sandset PM, et al. Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER). Thromb Res. 2022;213:119-24.
RAHIMI, Kazem, BHALA, Neeraj, KAMPHUISEN, Pieter, et al. Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. PLoS Med. 2012, vol. 9, no 9.
Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2000;20(2):556-62.
Baxi S, Crandall DL, Meier TR, Wrobleski S, Hawley A, Farris D, et al. Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis. J. Thromb. Haemost. 2008;99(04):749-58.
Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002;105(15):1756-9.
Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112(5):720-6.
Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation. 2012;126(1):92-103.
AlKhalfan F, Kerneis M, Nafee T, Yee MK, Chi G, Plotnikov A, et al. D-dimer levels and effect of rivaroxaban on those levels and outcomes in patients with acute coronary syndrome (an ATLAS ACS-TIMI 46 trial substudy). Am J Cardiol. 2018;122(9):1459-64.
Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. J. Thromb. Haemost. 2010;104(11):976-83.
Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-6.
Utne K, Dahm A, Wik H, Jelsness-Jørgensen L, Sandset P, Ghanima W. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res. 2018;163:6-11.
Prandoni P, Ageno W, Mumoli N, Zanatta N, Imberti D, Visonà A, et al. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res. 2017;153:97-100.
Cheung YW, Middeldorp S, Prins MH, Pap AF, Lensing AW, Arina J, et al. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. J. Thromb. Haemost. 2016;116(10):733-8.
- Abstract Viewed: 284 times
- pdf Downloaded: 470 times
